NL-OMON31126已完成3 期
A multi-center, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (16 to 70 years old) with Partial Onset Seizures. - Protocol N01252
CB Pharma0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Subjects from 16 to 70 years, both inclusive. Subjects under 18 years may only be included where legally permitted and ethically accepted.
- •Well-characterized focal epilepsy or epileptic syndrome according to the ILAE classification (1).
- •Subjects with a history of partial onset seizures whether or not secondarily generalized (Type I seizures according to the ILAE classification (2)).
- •Subjects having at least two partial onset seizures whether or not secondarily generalized per month during the three months preceding Visit 1 (V1).
- •Subjects having at least eight partial onset seizures whether or not secondarily generalized during the 8-week Baseline Period.
- •Subjects being uncontrolled while treated by one to two permitted concomitant AED(s).
排除标准
- •History or presence of seizures occurring only in clusters (too frequently or indistinctly separated to be reliably counted) before V3.
- •History or presence of status epilepticus during the year preceding V1 or during baseline.
- •Subject taking any drug with possible relevant CNS effects except if stable from at least 1 month before Visit 1 and expected to be kept stable during the Treatment Period.
- •Subjects taking any drug that may significantly influence the metabolism of BRV (CYP2C or CYP3A potent inducers/inhibitors) except if the dose has been kept stable at least one month before V1, and is expected to be kept stable during the Treatment Period.
- •History of cerebrovascular accident (CVA), including transient ischemic attack (TIA), in the last six months.
- •Presence of any sign (clinical or imaging techniques) suggesting rapidly progressing (i.e. not expected to stay stable during trial participation) brain disorder or brain tumor. Stable arteriovenous malformations, meningiomas or other benign tumors may be acceptable.
研究者
相似试验
进行中（未招募）
1 期
A multi-center, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (>= 16 to 70 years old) with Partial Onset Seizures.Estudio multicentrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos: evaluacion de la eficacia y la seguridad del brivaracetam en sujetos (edad >= 16 a 70 anos) con crisis de inicio parcial. - POS Phase 3Partial Onset SeizuresCrisis de inicio parcialMedDRA version: 9.1Level: LLTClassification code 10015037Term: EpilepsyEUCTR2006-006344-59-ESCB Pharma399
进行中（未招募）
不适用
A multi-center, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (>= 16 to 70 years old) with Partial Onset Seizures. - POS Phase 3EUCTR2006-006344-59-NLCB Pharma500
进行中（未招募）
1 期
A multi-center, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (>= 16 to 70 years old) with Partial Onset Seizures. - POS Phase 3Partial Onset SeizuresMedDRA version: 9.1Level: LLTClassification code 10015037Term: EpilepsyEUCTR2006-006344-59-FRCB Pharma399
进行中（未招募）
1 期
A multi-center, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (>= 16 to 70 years old) with Partial Onset Seizures. - POS Phase 3Partial Onset SeizuresMedDRA version: 9.1 Level: LLT Classification code 10015037 Term: EpilepsyEUCTR2006-006344-59-GBCB Pharma399
进行中（未招募）
不适用
A multi-center, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (>= 16 to 70 years old) with Partial Onset Seizures. - POS Phase 3Partial Onset SeizuresMedDRA version: 9.1Level: LLTClassification code 10015037Term: EpilepsyEUCTR2006-006344-59-BECB Pharma S.A.500